Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism

Noel C Chan1,2
Vinai Bhagirath1,3
John W Eikelboom1,3,4
1Population Health Research Institute, Hamilton, ON, Canada; 2Department of Haematology, Monash Medical Center, Clayton, VIC, Australia; 3Thrombosis and Atherosclerosis Research Institute, 4Department of Medicine, McMaster University, Hamilton, ON, Canada

Abstract: Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a common and potentially preventable cause of morbidity and mortality. Unfractionated heparin, low-molecular-weight heparin, and warfarin have been the cornerstone of VTE prevention and treatment but are being replaced by recently approved non-vitamin K antagonist oral anticoagulants (NOACs): dabigatran, rivaroxaban, apixaban, and edoxaban. The NOACs are at least as effective and as safe as heparins and warfarin for VTE prevention and treatment and are more convenient because they have a low propensity for food and drug interactions and are given in fixed doses without routine coagulation monitoring. The remaining limitations of currently available NOACs include their dependence on renal and hepatic function for clearance, and the lack of an approved antidote. Betrixaban is a new NOAC with distinct pharmacological characteristics: minimal renal clearance, minimal hepatic metabolism, and long half-life. It has undergone successful Phase II studies in orthopedic thromboprophylaxis, and in stroke prevention in atrial fibrillation. Currently, it is being evaluated in a Phase III trial of extended thromboprophylaxis in medical patients (APEX study). In this article, we describe the development of betrixaban, review its pharmacological profile, discuss the results of clinical trials, and examine its potential for VTE prevention and treatment.

Keywords: betrixaban, factor Xa inhibitors, anticoagulant, pharmacology, venous thromboembolism

Introduction
Venous thromboembolism (VTE), manifesting as either a deep vein thrombosis (DVT) or a pulmonary embolism (PE), is an important cause of morbidity and mortality worldwide and a leading cause of preventable death in hospitalized patients.1,2 The heparins (unfractionated heparin low-molecular-weight heparin [LMWH]) and warfarin have been the cornerstone of VTE prevention and treatment for more than half a century.3 Although effective, they have well-known limitations.4 In an attempt to overcome those limitations, orally administered direct thrombin inhibitors and direct factor Xa (FXa) inhibitors were developed and were evaluated in large Phase III trials for VTE treatment and prevention.5 Four non-vitamin K antagonist oral anticoagulants (NOACs), namely, dabigatran, rivaroxaban, apixaban, and more recently, edoxaban, have been shown to be at least as effective and safe as warfarin for VTE treatment and are now approved for this indication.6–11 They have also been approved for VTE prevention in major orthopedic surgery. Similar to the heparins, NOACs have rapid onset of action, and the peak plasma level is reached within 3 hours of administration. In contrast to the heparins, they have the advantage of oral administration, and in
contrast to warfarin, they have predictable pharmacology, less variability in anticoagulant effect, and less drug/food interactions, leading to the convenience of fixed dosing without the need for monitoring.

With the availability of four NOACs competing for similar indications, any additional NOAC would ideally need to have unique pharmacological properties that overcome existing limitations or be developed for an indication that fills an unmet need. Because of their reliance on renal clearance and hepatic metabolism, the currently approved NOACs have the potential to accumulate in patients with severe renal or liver impairment, and caution is required with rivaroxaban, apixaban, and edoxaban when administered concomitantly with potent cytochrome 450 (CYP450) inducers or inhibitors. Furthermore, due to their short half-lives resulting in relatively rapid offset of action, missing doses may predispose patients to thrombosis. Betrixaban, a new direct FXa inhibitor, stands out because it has the lowest renal clearance (<7% of administered dose), minimal hepatic metabolism (<1%), and a long half-life (terminal half-life =37 hours). Betrixaban has been tested in Phase II studies for VTE prevention in total knee replacement (EXPERT trial) and for stroke prevention in atrial fibrillation (EXPLORE-Xa trial),12,13 and it is currently being evaluated in a Phase III trial (APEX) for extended thromboprophylaxis in medical patients at high risk of VTE, an indication for which there is no approved anticoagulant.14 If this clinical development program succeeds, betrixaban could be the fifth NOAC to be introduced for the management of VTE. In this article, we describe the development of betrixaban, review its pharmacological profile, discuss the results of clinical trials, and examine its potential for VTE prevention and treatment.

Chemical development
Betrixaban is a direct FXa inhibitor developed by Portola Pharmaceuticals Inc. (San Francisco, CA, USA). It is derived from 1, N-(5-chloropyridin-2-yl)-2-(4-(N, N-dimethylcarbamimidoyl)-benzamido)benzam ide, an anthranilamide-based compound with potent FXa inhibitory activity (IC50 3 nM, Ki 1.4 nM).15 Through an iterative process, several analogs of the parent compound were synthesized by substitution at three phenyl rings, and the potential candidate compounds were selected on the basis of FXa inhibitory activity by performing structure–activity relationship studies. Many of the selected compounds, however, also showed high affinity toward hERG channel – a cardiac potassium ion channel that mediates cardiac repolarization. Inhibition of hERG channels is associated with delayed cardiac repolarization, QT prolongation, and the risk of life threatening arrhythmias, raising safety concerns. Subsequent structure–activity relationship studies led to the selection of the methoxy-substituted compound 11, as the candidate drug for further development because it retained potent selective FXa inhibition (IC50 =1.5 nM, Ki =0.117), least hERG channel binding (IC50 =8.9 µM), and an acceptable pharmacokinetic/pharmacodynamic profile in animal models.15

Pharmacological profile of betrixaban
Preclinical studies
Several preclinical studies were performed to establish the mechanism of action of betrixaban and to define an effective and safe antithrombotic dose. As detailed later, these studies confirmed that betrixaban exerts its antithrombotic effect by inhibiting free and prothrombinase-bound FXa in a concentration-dependent manner.12,15-17 They also suggest that betrixaban in concentrations ranging from 5 ng/mL to 25 ng/mL might produce clinically effective antithrombotic effect in humans.13

Effects on in vitro assays
In a whole blood prothrombinase inhibition assay, betrixaban showed dose-dependent inhibition of platelet-mediated prothrombinase activity consistent with its mechanism of action.16 For equivalent anti-FXa activities, betrixaban was more potent at inhibiting TAT complex and F1+2 generation compared to fondaparinux.17 In a tissue factor-induced thrombin generation assay, betrixaban in concentrations ranging from 5 ng/mL to 25 ng/mL inhibited thrombin generation to a comparable degree as trough, and the peak levels were achieved by 2.5 mg fondaparinux.17 Preclinical toxicology studies using patch clamp hERG assays showed that betrixaban was not a potent hERG channel inhibitor (IC50 =8.9 µM).15 They also suggest that the doses of betrixaban that will be clinically used would provide a 30-fold margin of safety (ratio of hERG IC50 to expected peak plasma concentration of betrixaban) against significant hERG channel inhibition.15

Effects on venous and arterial thrombosis in animal models
The antithrombotic efficacy of betrixaban was evaluated in three animal models: i) rabbit vena cava model, ii) rodent ferric chloride carotid artery model, and iii) baboon AV
shunt model. In the rabbit abdominal vena cava model of clot accretion on cotton threads, betrixaban in doses of 3 mg/kg showed nearly comparable inhibition of thrombus mass to enoxaparin 1.6 mg/kg (76% vs 96% inhibition). Betrixaban in doses of 19.1 mg/kg was at least as effective at maintaining patency as enoxaparin 7.6 mg/kg and clopidogrel 3 mg/kg/d (90% vs 70% vs 80% patency, respectively) in the ferric chloride injury model of rodent carotid artery. Finally, betrixaban demonstrated the dose-dependent inhibition of 111-Indium (111-In)-labeled platelet deposition at both the venous and arterial side of the baboon AV shunt thrombosis model when used in doses ranging from 0.05 mg/kg to 0.49 mg/kg. This dose range produced an average plasma concentration of 7–83 ng/mL and resulted in 30%–90% inhibition of platelet deposition at the venous side of the AV shunt.

Effects on ex vivo coagulation testing of animal and human plasma
To establish the usefulness of coagulation assays in predicting antithrombotic efficacy and in measuring the anticoagulant effect of betrixaban, several assays were tested in ex vivo samples. Clotting assays, including prothrombin time (PT), activated partial thromboplastin time (aPTT), and activated clotting time (ACT), were relatively insensitive to the anticoagulant effect of betrixaban and showed a differential species response. Doubling of PT was attained at 8.9 μM, 1.6 μM, 1.0 μM, and 0.4 μM concentrations in rat, rabbit, baboon, and human plasma, respectively. Based on the available data, doubling of PT in human would require a concentration of ~180 ng/mL, which is well above the purported clinically effective antithrombotic concentration range of 5–25 ng/mL. Thus, at concentrations that produced an antithrombotic effect, betrixaban is not expected to cause significant prolongation of PT in human. Detailed data for aPTT and ACT have not been published, but these assays are likely to be as insensitive to the anticoagulant effect of betrixaban as the PT. The prothrombinase inhibition and the anti-FXa assays are more sensitive to the effect of betrixaban than clotting assays and may be useful in measuring its antithrombotic effect. Of the two assays, suppression of thrombin generation measured by the prothrombinase inhibition assay correlated best with the antithrombotic activity of the drug in the baboon AV shunt model (correlation coefficient, \( R^2 = 0.99 \)).

Because the routinely available clotting assays, PT or aPTT, are relatively insensitive to levels achieved therapeutically, measurement and quantitation of betrixaban level in clinical practice will require the use of other tests such as the anti-FXa assay, as exemplified by current practice with other established FXa inhibitors.

Pharmacokinetics of betrixaban
Similar to other approved direct FXa inhibitors, betrixaban at a dose of 80 mg showed rapid absorption and peak plasma concentration within 3–4 hours of oral administration in healthy human volunteers. The oral bioavailability is 34% and is affected by fatty food, which reduces the peak concentration and area under the curve by 50%. About 60% of the drug is protein bound in plasma.

Betrixaban is primarily excreted in the gut (82%–89%) through the hepatobiliary route, likely via permeability glycoprotein (P-gp) efflux pump as mostly unchanged drug. Betrixaban is minimally metabolized (<1%) by CYP450 enzymes and does not induce or inhibit CYP450. It has the least renal clearance of all approved NOACs so far (5%–7% of orally administered dose).

The terminal half-life (time for concentration to be reduced by 50%) is 37 hours, and the pharmacodynamic half-life (time for efficacy to be reduced by 50%) is ~20 hours. As a consequence, betrixaban exhibits a low peak-to-trough drug concentration ratio.

Comparative pharmacology and clinical implications
In comparison to other approved NOACs (Table 1), betrixaban stands out on account of four characteristics: the least renal clearance, the least hepatic metabolism, the most gastrointestinal (GI) clearance, and the longest half-life. Thus, the dependence on renal clearance of approved NOACs varies from 80% with dabigatran to 66%, 35%, and 25% with rivaroxaban, edoxaban, and apixaban, respectively. Since only 5%–7% of orally administered betrixaban is renally cleared, its unique pharmacological profile may allow broader use to include patients with renal impairment (CrCl < 30 mL/min), a population excluded from previous NOAC trials and with limited anticoagulant option. With minimal hepatic metabolism (<1%), drug-to-drug interaction occurring as a result of CYP450 induction or inhibition is unlikely, and the accumulation in patients with liver impairment would be less likely. However, based on its reliance on the hepatobiliary system as a main mechanism of clearance, accumulation may be expected to occur in obstructive jaundice. Because betrixaban is a substrate for P-gp, drug-to-drug interaction is expected...
**Table 1** Comparative pharmacology of non-vitamin K antagonist oral anticoagulants

<table>
<thead>
<tr>
<th></th>
<th>Dabigatran</th>
<th>Rivaroxaban</th>
<th>Apixaban</th>
<th>Edoxaban</th>
<th>Betrixaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target</td>
<td>IIa</td>
<td>Xa</td>
<td>Xa</td>
<td>Xa</td>
<td>Xa</td>
</tr>
<tr>
<td>Bioavailability</td>
<td>6%–7%</td>
<td>66%</td>
<td>50%</td>
<td>62%</td>
<td>34%</td>
</tr>
<tr>
<td>Protein binding</td>
<td>35%</td>
<td>92%–95%</td>
<td>87%</td>
<td>40%–59%</td>
<td>60%</td>
</tr>
<tr>
<td>T&lt;sub&gt;max&lt;/sub&gt; (h)</td>
<td>2</td>
<td>2–4</td>
<td>1–3</td>
<td>1–2</td>
<td>3–4</td>
</tr>
<tr>
<td>Metabolism via CYP450</td>
<td>&lt;2%</td>
<td>57%</td>
<td>&lt;32%</td>
<td>&lt;25%</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>Renal excretion</td>
<td>&gt;80%</td>
<td>66%</td>
<td>25%</td>
<td>35%</td>
<td>6%–13%</td>
</tr>
<tr>
<td>Fecal excretion</td>
<td>82%–88%</td>
<td>26.4%</td>
<td>46.7%–56%</td>
<td>62.2%</td>
<td>82%–89%</td>
</tr>
<tr>
<td>T&lt;sub&gt;1/2&lt;/sub&gt; (h)</td>
<td>12–14</td>
<td>9–13</td>
<td>8–15</td>
<td>9–11</td>
<td>37 (PD T&lt;sub&gt;1/2&lt;/sub&gt; = 20 h)</td>
</tr>
</tbody>
</table>

Abbreviations: T<sub>max</sub>, time to reach peak concentration in plasma after oral dose; h, hours; CYP450, cytochrome 450; T<sub>1/2</sub>, terminal half-life of drug; PD T<sub>1/2</sub>, pharmacodynamic half-life.

Chang et al 2015:11

Vascular Health and Risk Management 2015:11

Submitted for consideration | www.dovepress.com | by 54.70.40.11 on 26 Aug 2019

for personal use only.

Power||TCPDF (www.tcpdf.org)

1 / 1

Vascular Health and Risk Management downloaded from https://www.dovepress.com/ by 54.70.40.11 on 26-Aug-2019

For personal use only.

To occur with potent P-gp inhibitors. Thus, concomitant administration of strong P-gp inhibitors (ketocazozole, amiodaron, and diltiazem) increases betrixaban concentration around twofold. Additionally, because >82% unchanged drug is cleared via the GI tract, GI side effects may be more pronounced.

Although the long half-life and a low peak-to-trough drug concentration ratio should minimize anticoagulant variability thereby ensuring a consistent anticoagulant effect over a 24 hours period and minimizing the effect of a missed dose, it could be problematic in patients who bleed or who require urgent surgery in the absence of an antidote.

**Early clinical studies: dose finding, clinical efficacy, and safety**

Doses for Phase II studies were selected to achieve a target concentration range of 5–25 ng/mL based on the results of a comparative in vitro study that showed a similar degree of inhibition of thrombin generation to fondaparinux 2.5 mg (an established VTE prevention dose) and the results of concentration–response relationship from the baboon AV shunt model. Selection of the oral dose range (30–80 mg) was subsequently informed by pharmacokinetic data obtained from Phase I studies in healthy humans, which suggested that this dose range would produce concentrations spanning the target concentration range. Betrixaban subsequently underwent Phase II studies in orthopedic thromboprophylaxis (EXPERT trial), and in atrial fibrillation (EXPLORE-Xa trial), respectively. Despite the long half-life of betrixaban, twice daily doses (15 mg bid and 40 mg bid) were compared to enoxaparin 30 mg bid in the EXPERT trial. As discussed by the investigators, a bid dosing regimen was selected to mimic a possible future controlled-release formulation and to examine its effect on reducing diurnal variability in the anticoagulant effect of betrixaban. In EXPLORE-Xa, daily doses of 40 mg, 60 mg, and 80 mg were compared to warfarin.

**Phase II EXPERT trial: VTE prevention in total knee replacement**

The EXPERT trial (n=214) was an open-label blinded-endpoint Phase II randomized controlled trial comparing the efficacy and safety of two betrixaban doses, 15 mg bid and 40 mg bid administered 6–8 hours postoperatively, with enoxaparin 30 mg sc bid, administered 12–24 hours postoperatively, in patients undergoing total knee replacement (Table 2).

The primary efficacy outcome was the occurrence of objectively diagnosed VTE, a composite of symptomatic VTE and venographic DVT. The safety outcome was the occurrence of clinically relevant bleeding, a composite of major and clinically significant nonmajor bleeding. The primary efficacy outcome occurred in 20% (95% confidence interval [CI]: 11.4%–31.3%), 15% (95% CI: 7.6%–26.5%), and 10% (95% CI: 2.8%–23.7%) of patients receiving betrixaban 15 mg bid, 40 mg bid, and enoxaparin 30 mg bid, respectively (Figure 1). Although betrixaban was associated with higher point estimates for thrombosis than enoxaparin, the event rates were not statistically different among the three arms. The corresponding clinically relevant bleeding rates were 0% (95% CI: 0%–4.2%), 2.4% (95% CI: 0.3%–8.3%), and 7% (95% CI: 1.5%–19.1%), respectively (Figure 1). Because the clinical efficacy outcome data were not adequately informative for dose finding, additional comparative sub-studies using FXa inhibition and suppression of thrombin generation as surrogate outcomes were performed. In these studies, betrixaban 40 mg bid showed similar anti-FXa activity as enoxaparin 30 mg bid, but greater suppression of thrombin generation than the latter. The 15 mg bid dose showed lower FXa inhibition than enoxaparin but similar decrease in thrombin generation. It is unknown whether...
these favorable surrogate results will translate into clinical efficacy.

**EXPLORE-Xa trial: dose ranging study for stroke prevention in AF**

The safety and tolerability of three blinded doses of betrixaban – 40 mg daily, 60 mg daily, and 80 mg daily – were compared to open-label warfarin in patients with nonvalvular atrial fibrillation in the dose ranging EXPLORE-Xa trial (n=561) (Table 2). Although the trial did not exclude patients with severe renal impairment, only a minority of patients (8.1%) with glomerular filtration rate (GFR) <40 mL/min at baseline were enrolled. The primary safety outcome was the occurrence of clinically relevant bleeding, a composite of major and clinically relevant nonmajor bleeding. Secondary outcomes included all bleeding, death, ischemic and nonischemic stroke, MI, or systemic embolism rates. All three doses of betrixaban (40 mg, 60 mg, and 80 mg) showed lower point estimates for bleeding (0.78%, 3.94%, and 3.94%, respectively) than warfarin (5.51%). Only betrixaban 40 mg daily showed statistically significant reduced bleeding than warfarin (hazard ratio [HR] =0.14, P=0.04) (Figure 2).

In total, two ischemic strokes (in 60 mg and 80 mg betrixaban arms) and two vascular deaths (in 40 mg betrixaban and warfarin arms) occurred; these low event rates do not allow definitive conclusions to be made about relative efficacy. Surrogate outcomes of D-dimer and prothrombinase inhibition were also measured for population pharmacokinetic/pharmacodynamic modeling substudies. All three doses of betrixaban suppressed D-dimer and thrombin generation, but only the 80 mg daily dose resulted in suppression of thrombin generation to a level similar to that achieved by warfarin at a therapeutic international normalized ratio.
Safety and tolerability in early studies

Bleeding

The pooled rate of clinically relevant bleeding was lower for betrixaban than control in both EXPERT (betrixaban vs enoxaparin: 1.2% vs 6.9%) and EXPLORE-Xa (betrixaban vs warfarin: 2.9% vs 5.5%). These results suggest that betrixaban in the dose range of 30–80 mg is at least as safe as enoxaparin for orthopedic thromboprophylaxis and as warfarin for stroke prevention in patients with AF.

GI and hepatic adverse events

In EXPLORE-Xa, a significantly higher rate of diarrhea (6.0% vs 0.8%) was observed in the betrixaban arms than the warfarin arm. Similarily, higher rates of nausea (11% vs 1.6%), dyspepsia (3.1% vs 0.8%), and vomiting (4.7% vs 0.8%) were reported with betrixaban 80 mg daily than warfarin. However, most of the GI adverse events were mild and did not result in discontinuation of study drug.

A significant hepatotoxicity signal was not observed in Phases I and II studies. The rate of elevated alanine aminotransferase (>3 times upper limit of normal) was not worse than control in EXPLORE-Xa (betrixaban vs warfarin: 1.8% vs 0.3%) and EXPERT study (betrixaban vs enoxaparin: 2.0% vs 5.3%, at discharge). The elevation in alanine aminotransferase was transient and did not show evidence of a dose-dependent response. Importantly, no case of elevated bilirubin was observed with betrixaban in the early clinical studies.

QTc prolongation

Betrixaban is derived from a class of compounds that has the potential to prolong the QTc interval through hERG channel inhibition and to cause cardiac arrhythmia. QTc prolongation was investigated in a single-dose crossover toxicology study in 96 healthy volunteers performed to meet ICH E14 regulatory requirements and in the EXPERT study. The first study showed that a single dose of betrixaban of either 80 mg or 140 mg was not associated with prolongation of QTc above the regulatory threshold (upper 95% CI for the mean estimate of the difference of QTc from baseline <10 ms). Also, comparison of baseline and on treatment electrocardiograms (ECGs) in the EXPERT study did not show a significant effect of betrixaban on QTc interval.

Clinical development in Phase III trial

To ensure a competitive edge over the approved NOACs, the clinical development of betrixaban is targeting perceived unmet clinical needs, while taking advantage of its unique pharmacokinetic profile, namely minimal renal clearance. At the time of publication of this manuscript, one Phase III trial is ongoing in VTE prevention, and none in VTE treatment.

Acute medically ill VTE prevention with extended duration betrixaban (APEX) study

Although NOACs and LMWH are approved for extended VTE prophylaxis in major orthopedic surgery, and for high-risk surgery, there is currently no approved anticoagulant for extended VTE prophylaxis in medically ill patients. To address this need, the APEX study is evaluating the safety and efficacy of extended duration betrixaban (for up to 35 days) in acute medically ill patients at high risk of VTE. APEX is a double-blind, double dummy, parallel-group, multicenter randomized controlled trial (RCT) (n=6,850) comparing betrixaban 80 mg once daily for 35–42 days with enoxaparin 40 mg once daily for 6–14 days. Patients with severe renal impairment (CrCl <30 mL/min), but not end stage renal failure (CrCl <15 mL/min or receiving dialysis), are being included for the first time in a Phase III NOAC trial and will receive 50% reduced dose of study medications based on the findings from pharmacometric modeling. The primary efficacy outcome is a composite of asymptomatic proximal DVT (as detected by mandatory ultrasound), symptomatic DVT, nonfatal PE, and VTE-related...
death between days 35 and 42. The primary safety outcome is the occurrence of major bleeding through 7 days after discontinuation of study medications. Betrixaban 80 mg daily was selected based on the pharmacometric modeling of anti-Xa activity and suppression of thrombin generation in the Phase II studies. Study completion is expected by September 2015.14,26

Extended thromboprophylaxis with anticoagulant in medical patients is a challenge because of the heterogeneity of this population leading to wide variability in VTE risk and because of the risk of bleeding. Previous RCTs evaluating extended thromboprophylaxis in relatively unselected medical patients have consistently failed to show a clear net benefit of extended duration thromboprophylaxis when compared to standard (7–10 days) prophylaxis with LMWH (Table 3).27–29 Reasons for the lack of net benefit in these trials include the following: inclusion of a population that was not at high enough risk of VTE (control VTE risk <5%) and an excess in bleeding (2.5 times control rate) offsetting the modest efficacy benefit (Table 3). Patient selection on the basis of VTE and bleeding risk is therefore a key determinant of trial success.

To address the challenges of extended VTE prophylaxis in medical patients, the APEX study uses an enrichment design, in which patients at high risk of VTE are selected based on patient/disease-related factors and/or the results of D-dimer performed at baseline.14,30 As well as informing on the efficacy and safety of extended duration of VTE prophylaxis with betrixaban, the study will inform on the clinical utility of the risk stratification methods used.30 By selecting patients on the basis of clinical features and a biomarker, it is hypothesized that a higher VTE risk population will be enrolled (estimated VTE risk in control arm at least 7.5% at day 35) when compared to previous studies.14 Similarly, by using stringent exclusion criteria, it is hypothesized that a population at lower risk of bleeding will be selected. While there is evidence supporting the clinical validity of risk stratification of patients on the basis of clinical features and D-dimer,31–35 there is presently no validated bleeding risk stratification tool for medical patients. Moreover, if the same clinical features or laboratory markers that identify patients with high VTE risk predict increased bleeding risk, the putative benefit of the risk stratification strategy may be diminished.

### Potential role of betrixaban in VTE prevention and treatment

The results of the APEX study will be critical to the future prospects of betrixaban. First, if the trial shows that extended duration betrixaban is more effective than 6–14 days of enoxaparin with no appreciable increase in bleeding, betrixaban could be the first NOAC approved for extended thromboprophylaxis in medical patients. In addition, such evidence may launch future clinical development in other thromboprophylaxis indications and in VTE treatment. Second, a favorable efficacy and safety in patients with severe renal impairment would act as a proof of concept and support further evaluation of betrixaban in this population with limited anticoagulant options.

As exemplified by previous trials of the approved NOACs, confirmation of the clinical efficacy and safety of the selected dose in VTE prevention is often a determinant of success for future studies in VTE treatment and stroke prevention in AF. Because the APEX study is comparing the strategy of extended thromboprophylaxis with standard thromboprophylaxis with a single outcome assessment at days 35–42, it does not directly inform on the relative clinical efficacy

<table>
<thead>
<tr>
<th>Study (no of patient)</th>
<th>Population</th>
<th>Intervention</th>
<th>Control</th>
<th>All VTE rate (intervention vs control)</th>
<th>Major bleeding rate (intervention vs control)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXCLAIM10</td>
<td>Acutely ill medical patient</td>
<td>Extended duration enoxaparin</td>
<td>Enoxaparin</td>
<td>2.5% vs 4.0%</td>
<td>0.8% vs 0.3%</td>
<td>No net benefit</td>
</tr>
<tr>
<td>ADOPT19</td>
<td>Acutely ill medical patient</td>
<td>Extended duration apixaban</td>
<td>Enoxaparin</td>
<td>2.7% vs 3.1%</td>
<td>0.5% vs 0.2%</td>
<td>No net benefit</td>
</tr>
<tr>
<td>MAGELLAN29</td>
<td>Acutely ill medical patient</td>
<td>Extended duration rivaroxaban</td>
<td>Enoxaparin</td>
<td>4.4% vs 5.7%</td>
<td>1.1% vs 0.4%</td>
<td>No net benefit</td>
</tr>
<tr>
<td>APEX8 (n=8,650) ongoing</td>
<td>Acutely ill medical patient</td>
<td>Extended duration betrixaban</td>
<td>Enoxaparin</td>
<td>Awaited</td>
<td>Awaited</td>
<td>Enrichment design. Enrolling only patients at high VTE risk. Expected all VTE rate in control arm =7.5%</td>
</tr>
</tbody>
</table>

**Abbreviations:** VTE, venous thromboembolism; RCTs, randomized controlled trials.

---

**Table 3 RCTs evaluating extended thromboprophylaxis in acutely ill medical patient**
and safety of the selected dose of betrixaban in comparison to enoxaparin. Before proceeding to Phase III VTE treatment studies, it would be prudent to perform dose finding study in VTE treatment to select optimal treatment dose.

The lack of antidote remains a concern for the NOACs because it complicates the management of patients who experience life-threatening bleeding or who require emergency surgery. Because of its long half-life, betrixaban is particularly vulnerable to this concern. Successful codevelopment of Portola’s antidote—Andexanet alfa, an inactive recombinant FXa—will help allay this concern by providing a ready means to reverse the anticoagulant effect of betrixaban.36-42

Conclusion
Betrixaban is a new FXa inhibitor with unique pharmacokinetic characteristics: minimal renal clearance, minimal hepatic metabolism, and a long half-life. Minimal renal clearance is the most pertinent attribute, which may offer a competitive edge over the approved NOACs, particularly if betrixaban shows favorable efficacy and safety profile in patients with severe renal failure, a population with unmet need. Extended medical thromboprophylaxis is an indication with no competition from other NOACs, but it is also a challenging indication for which a net clinical benefit has remained elusive. The design of the APEX study reflects lessons learnt from previous RCTs with the NOACs and has benefited from recent validation of clinical risk assessment models and laboratory markers such as d-dimer.14 Success in the APEX study is critical for the future clinical development of betrixaban.

Disclosure
JWE reports grant support and honoraria from Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers-Squibb/Pfizer, Daiichi Sankyo, Glaxo Smith Kline, Janssen, and Sanofi-Aventis and grant support from Eli Lilly. NCC reports travel grant support from Sanofi-Aventis. The other author reports no conflicts of interest in this work.

References


